Benefits of screening for latent Mycobacterium tuberculosis infection

Archives of Internal Medicine

Volumn 160, Issue 10, 2000, Pages 1513-1521

  Rose, David N ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROBABILITY; SCREENING; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0034701829     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.10.1513     Document Type: Article

References (104)

1. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk populations. MMWR Morb Mortal Wkly Rep. 1995;44(RR-11):3-17.
2. Reider HL, Cauthen GM, Comstock GW, Snider DE Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989;11:79-98.
3. Dooley SW, Castro KG, Snider DE Jr. Perspectives on the elimination of tuberculosis in the United States. In: Rom WN, Garay SM, eds. Tuberculosis Boston, Mass: Little Brown & Co; 1996:973-982.
4. Barnes PF. Reducing ongoing transmission of tuberculosis. JAMA. 1998;280: 1702-1703.
5. American Thoracic Society. Preventive treatment of tuberculosis. Am Rev Respir Dis. 1971;104:460-463.
6. Centers for Disease Control and Prevention. The use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1990;39(RR-8):6-8.
7. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins; 1996:277-286.
8. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-1374.
9. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-272.
10. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801-808.
11. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351:786-792.
12. Gordin F, Chaisson R, Matts J, et al. A randomized trial of 3 months of rifampin (RIF) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive (+), PPD+ patients (pts). Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 5, 1998; Chicago, Ill.
13. Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med. 1981;94:808-813.
14. Rose DN, Schlechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA. 1986;256: 2709-2713.
15. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215-220.
16. Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med. 1990:150:2517-2522.
17. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
18. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
19. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317:307-312.
20. Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA. 1994;272:535-539.
21. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia: twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 1976;91:276-280.
22. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: final report to the Medical Research Council. BMJ. 1977;2:293-295.
23. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28-106.
24. Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med. 1995; 122:906-912.
25. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99:131-138.
26. Shaw JB. Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc. 1954;69:724-732.
27. Chapman JS, Dyerly MD. Social and other factors in intrafamilial transmission of tuberculosis. Am Rev Respir Dis. 1964;90:48-60.
28. Riley RL, Moodie AS. Infectivity of patients with pulmonary tuberculosis in inner city homes. Am Rev Respir Dis. 1974;110:810-812.
29. Rose CE, Zerbe GO, Lantz SO, Bailey WC. Establishing priority during investigation of tuberculosis contacts. Am Rev Respir Dis. 1979;119:603-609.
30. Vennema A. Contact investigation and isoniazid chemoprophylaxis in New York City, 1979-1987. N Y State J Med. 1992;92:185-188.
31. Beyers N, Gie RP, Schaaf HS, et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:38-43.
32. Menzies D. Issues in the management of contacts of patients with active pulmonary tuberculosis. Can J Public Health. 1997;88:197-201.
33. Gessner BD, Weiss NS, Nolan CM. Risk factors for pediatric tuberculosis infection and disease after household exposure to adult index cases in Alaska. J Pediatr. 1998;132:509-513.
34. MacIntyre CR, Plant AJ. Preventability of incident cases of tuberculosis in recently exposed contacts. Int J Tuberc Lung Dis. 1998;2:56-61.
35. Grzybowski S, Allen EA, Black WA, et al. Inner-city survey for tuberculosis: evaluation of diagnostic methods. Am Rev Respir Dis. 1987;135:1311-1315.
36. Schluger NW, Huberman R, Wolinsky N, Dooley R, Rom WN, Holzman RS. Tuberculosis infection and disease among persons seeking social services in New York City. Int J Tuberc Lung Dis. 1997;1:31-37.
37. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol. 1975;101:363-382.
38. Morse DL, Hansen RE, Grabau JC, Cauthen G, Redmond SR, Hyde RW. Tuberculin conversions in Indochinese refugees: an assessment of boosting and anergy. Am Rev Respir Dis. 1985;132:516-519.
39. Perez-Stable EJ, Slutkin G, Paz A, Hopewell PC. Tuberculin reactivity in United States- and foreign-born Latinos: results of a community-based screening program. Am J Public Health. 1986;76:643-646.
40. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. Am Rev Respir Dis. 1988;137:805-809.
41. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest. 1993;103:1670-1674.
42. Trump DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the US Navy in 1990. Arch Intern Med. 1993;153:211-216.
43. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med. 1994;330:520-530.
44. Braun MM. Tuberculosis in correctional facilities. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. New York, NY: Marcel Dekker Inc; 1993:551-570.
45. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional facilities. MMWR Morb Mortal Wkly Rep. 1996;45(RR-8):1-27.
46. Jochem K, Tannenbaum TN, Menzies D. Prevalence of tuberculin skin test reactions among prison workers. Can J Public Health. 1997;88:202-206.
47. Centers for Disease Control. Tuberculosis and AIDS - Connecticut. MMWR Morb Mortal Wkly Rep. 1987;36:131-133.
48. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of child bearing age with HIV infection in Zaire. Am Rev Respir Dis. 1991;143:501-504.
49. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268:504-509.
50. Veugelers PJ, Cornelisse PGA, Craib KJP, et al. Models of survival in HIV infection and their use in the quantification of treatment benefits. Am J Epidemiol. 1998;148:487-496.
51. Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA. 1974;229:798-800.
52. Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med. 1979;67:597-602.
53. Sasaki S, Akiba T, Suenaga M, et al. Ten years† survey of dialysis-associated tuberculosis. Nephron. 1979;24:141-145.
54. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am J Med. 1980;68:59-65.
55. Rutsky EA, Rostand SG. Mycobacteriosis in patients with chronic renal failure. Arch Intern Med. 1980;140:57-61.
56. Malhotra KK, Parashar MK, Shrama RK, et al. Tuberculosis in maintenance haemodialysis patients: study from an endemic area. Postgrad Med J. 1981;57: 492-498.
57. Belcon MC, Smith EKM, Kahana LM, Shimizu AG. Tuberculosis in dialysis patients. Clin Nephrol. 1982;17:14-18.
58. Hsu KT, Lam KK, Liao SC, Liu CC, Chen JB. Prevalence of pulmonary tuberculosis in end-stage renal disease (ESRD) patients is not unusually high. Clin Nephrol. 1996;45:279-280.
59. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis. 1983; 5:216-226.
60. Quinibi WY, Al-Sibai MB, Taher S, et al. Mycobacterial infection after renal transplantation: report of 14 cases and review of the literature. Q J Med. 1990;77: 1039-1060.
61. United States Renal Data System. 1997 Annual data report, V: patient mortality and survival. Am J Kidney Dis. 1997;30(suppl 1):S86-S106.
62. Boucot KR, Dillon ES, Cooper DA, Meier P, Richardson R. Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc. 1952;65(suppl):1-50.
63. Silwer H, Oscarsson PN. Incidence and coincidence of diabetes mellitus and pulmonary tuberculosis in a Swedish county. Acta Med Scand. 1957;335(suppl): 3-48.
64. Kim SJ, Homg YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis. 1995;76:529-533.
65. Wong JS, Pearson DW, Murchison LE, Williams MJ, Narayan V. Mortality in diabetes mellitus: experience of a geographically defined population. Diabet Med. 1991;8:135-139.
66. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health. 1998;88:765-770.
67. Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc Pulm Dis. 1957; 76:517-539.
68. Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health. 1971;22:106-112.
69. Paul R. Silicosis in Northern Rhodesia copper miners. Arch Environ Health. 1961; 2:96-109.
70. Westerholm P, Ahlmark A, Maasing R, Segelberg I. Silicosis and risk of lung cancer or lung tuberculosis: a cohort study. Environ Res. 1986;41:339-350.
71. Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med. 1994;150:1460-1462.
72. Kleinschmidt I, Churchyard G. Variation in incidences of tuberculosis in subgroups of South African gold miners. Occup Environ Med. 1997;54:636-641.
73. Ng TP, Chan SL, Lee J. Predictors of mortality in Silicosis. Respir Med. 1992; 86:115-119.
74. Starzynski Z, Marek K, Kujawska A, Szymczak W. Mortality among different occupational groups of workers with pneumoconiosis: results from a register-based cohort study. Am J Ind Med. 1996;30:718-725.
75. Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. Thorax. 1968;23:571-581.
76. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol. 1972;49:329-336.
77. Kim HA, Yoo CD, Lee EB, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998;16:9-13.
78. Morrow LB, Anderson RE. Active tuberculosis in leukemia: malignant lymphoma and myelofibrosis. Arch Pathol. 1965;79:484-493.
79. Ruiz-Argüelles GJ, Mercado-Diaz MA, Ponce-De-León S, Ponce-De-León S, Pérez-Tamayo R. Studies on lymphomata, III: lymphomata, granulomata and tuberculosis. Cancer. 1983;52:258-262.
80. Thorn PA, Brookes VS, Waterhouse JAH. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. BMJ. 1956;1:603-608.
81. Phillips TJG. Influence of surgery for peptic ulcer on pneumoconiosis and tuberculosis. Br J Ind Med. 1970;27:245-249.
82. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med. 1979;139:337-339.
83. McAdam JM, Brickner PW, Scharer LL, Crocco JA, Duff AE. The spectrum of tuberculosis in a New York City men's shelter clinic (1982-1988). Chest. 1990; 97:798-805.
84. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health. 1991;81:1307-1310.
85. Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis. 1987;136:1188-1192.
86. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res. 1980;20:1-63.
87. Salpeter EE, Salpeter SR. Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol. 1998;142:398-406.
88. Borgdorff MW, Veen J, Kalisvaart NA, Nagelkerke N. Mortality among tuberculosis patients in the Netherlands in the period 1993-1995. Eur Respir J. 1998; 11:816-820.
89. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60:555-564.
90. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med. 1993;159:560-564.
91. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med. 1996;164:486-491.
92. Comstock GW. Evaluating isoniazid preventive therapy: the need for more data. Ann Intern Med. 1981;94:817-819.
93. Glassroth J. Tuberculosis prophylaxis with isoniazid [letter]. Ann Intern Med. 1981;95:517.
94. Snider DE Jr. Decision analysis for isoniazid preventive therapy: take it or leave it? Am Rev Respir Dis. 1988:137:2-4.
95. Loundon RG, Romans WE. Cough frequency and infectivity in patients with pulmonary tuberculosis [editorial]. Am Rev Respir Dis. 1969;99:109-111.
96. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis. 1985;132:125-132.
97. Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med. 1998;158:465-469.
98. National Center for Health Statistics. Vital Statistics of the United States, 1992, Volume II, Mortality, Part A. Washington, DC: US Public Health Service; 1996.
99. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data from outcomes. N Eng J Med. 1998;339:380-386.
100. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997:126:712-720.
101. Moriarty PM. Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results. Am J Cardiol. 1998;82:505-507.
102. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997;157:2617-2624.
103. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly: implications and generalizability of randomized trials. JAMA. 1994; 272:1932-1938.
104. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014-1018.